Table 3

Comparison of percent of cells positive for CD11b/CADO48A by gate amongst tumor types
Sarcoma Mean Median Min Max
Ungated 33.4±12.7 28.7 13.5 58.2
R1 29.9±12.5* 26.5 11.7 53.1
P1 29.0±12.6* 25.5 11.6 51.8
P2 25.1±12.0 22.4 8.2 50.6
P3 4.8±4.7 3.5 1.6 20.3
P4 4.7±2.9 3.8 1.1 12.6
Carcinoma
Ungated 30.4±14.8 23.8 11.4 64.5
R1 26.4±12.8* 21.5 8.5 55.6
P1 25.3±12.5* 21.0 7.2 53.6
P2 22.7±11.4 18.2 8.1 47.9
P3 3.7±1.9 3.1 1.2 8.0
P4 5.1±3.5 3.5 2.1 12.7
Melanoma
Ungated 56.0±15.2 53.5 42.3 72.3
R1 52.6±13.5* 51.0 40.0 66.9
P1 51.6±13.0* 50.2 39.3 65.2
P2 44.7±13.5 41.2 33.3 59.6
P3 7.8±2.2 7.7 5.7 10.1
P4 4.8±1.1 4.5 3.8 6.0

The percentage of cells staining positive for CD11b and CADO48A are displayed for each tumor subtype: sarcoma (n= 19), carcinoma (n=18) and melanoma (n=3). Patients were categorized into one of the three groups based on either cytology or histopathology. A statistical difference was seen in the R1 and P1 gates between the 3 tumor types on initial analysis. When the melanoma patients were excluded due to low patient numbers no statistical difference was seen in the percent of CD11b/CADO48A positive cells, in any gate, between the sarcoma or carcinoma patients. An * denoted statistical significance (p<0.05). All values are expressed as a percentage of all cells analyzed by flow cytometry.

Sherger et al.

Sherger et al. BMC Veterinary Research 2012 8:209   doi:10.1186/1746-6148-8-209

Open Data